The approval of milatuzumab, a humanized CD74-targeting antibody in human multiple myeloma and non-Hodgkin lymphoma (78), and ongoing development of antibodies that target MIF (79) provide candidates to test for therapeutic effects on PNs. This evidence concerns the gene CD74 and plasma cell myeloma.